CaRisto diagnostics

Caristo Diagnostics is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo’s award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention.

CaRi-Plaque^TM

Caristo’s FDA-cleared CaRi-Plaque™ technology is an AI-assisted image analysis application to aid the diagnosis of coronary artery disease (CAD).

• CaRi-Plaque technology determines the presence, extent and severity of coronary plaques and luminal stenosis to provide critical insights into coronary anatomy and plaque pathology.
• CaRi-Plaque builds on Caristo’s breakthrough core CaRi-Heart® technology. Its precision and accuracy have been comprehensively validated against expert clinical consensus.

CaRi-Heart^®

CaRi-Heart^® technology is a major breakthrough that quantifies coronary inflammation, a key driver of heart attacks, based on analysis of routine Coronary Computed Tomography Angiography (CCTA). Its novel imaging biomarker, the Fat Attenuation Index Score (FAI-Score™), predicts a patient’s risk of cardiac mortality up to 10 years in advance.

• CaRi-Heart analysis also generates an individualised risk score to aid diagnosis and management of coronary artery disease, predicting a patient’s risk of cardiac mortality years in advance.
• CaRi-Heart FAI-Score technology is exceptionally validated across >50,000 patients studied and published in leading medical journals.
• The CaRi-Heart software is a medical device that is regulatory cleared for use in the UK and EU and is currently available for research use only in the U.S.